Q-omics provides the consensus-scored IGLC4 profile across patient tissues and cancer cell-line models. IGLC4 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGLC4 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, IGLC4 RNA expression shows 5,785 significant pathway-activity associations, with the highest sampling consensus in SKCM. Together, these results highlight HNSC, COAD, and SKCM as cancer lineages where IGLC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLC4 survival associations across molecular data types. IGLC4 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLC4 RNA expression–survival associations across cancer types. High IGLC4 expression shows unfavorable associations in KIRP, STAD and KIRC, but favorable associations in HNSC, BRCA and DLBC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGLC4 RNA expression.
This table summarizes IGLC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGLC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLC4 shows lower tumor expression in COAD, READ and STAD and higher tumor expression in LUAD. The COAD box plot shows higher IGLC4 RNA expression in normal versus tumor tissue (log2 FC = −0.340, t-test p < 0.001).
This table shows molecular features associated with IGLC4 in patient tissues and cancer cell lines. In patient samples, IGLC4 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
